International Flavors & Fragrances Inc.

(New York Stock Exchange)
Back to all articles
Bullish +75

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC

AI-generated analysis

πŸ“ˆ IFF has agreed to sell its Food Ingredients business to CVC Capital Partners for approximately $4.3 billion in enterprise value.

πŸ’° The deal values the divested unit at a 10x EBITDA multiple, with IFF retaining a 10% minority equity stake worth roughly $200 million.

πŸ”„ This transaction is part of a broader portfolio simplification strategy where IFF has previously divested 13 non-core businesses for nearly $10 billion.

🎯 The sale allows IFF to focus exclusively on its three core innovation-driven segments: Taste, Scent, and Health & Biosciences.

πŸ’΅ IFF expects to receive net cash proceeds of approximately $3.8 billion after accounting for equity rollover, adjustments, and transaction costs.

πŸ“‰ Proceeds will be prioritized for debt reduction, targeted share repurchases, and reinvestment in high-return growth opportunities within the core portfolio.

⚠️ The company expects the deal to be dilutive to adjusted EPS in the first 12 months following closing before capital deployment benefits materialize.

πŸ“… The transaction is expected to close by the end of the second quarter of 2027, subject to regulatory approvals and customary conditions.

🀝 IFF will hold a board seat in the new company as part of its retained minority equity interest in the Food Ingredients business.

πŸ“Š In 2025, the divested Food Ingredients business generated nearly $3.1 billion in annual sales and approximately $430 million of EBITDA.

πŸš€ IFF reiterates its full-year 2026 guidance with sales expected between $10.5 billion and $10.8 billion.

πŸ’Ή For 2026, adjusted operating EBITDA is projected to range from $2.05 billion to $2.15 billion.

πŸ“ˆ The company expects comparable currency neutral sales growth of 1% to 4% for the full year 2026.

πŸ“ˆ Adjusted operating EBITDA growth is anticipated to be between 3% and 8% on a comparable currency neutral basis.

🏦 J.P. Morgan Securities LLC and BofA Securities are serving as financial advisors, while Skadden Arps serves as legal advisor.

Bullish Signals
  • IFF has entered into an agreement to sell its Food Ingredients business for approximately $4.3 billion, representing a 10x enterprise value-to-EBITDA multiple.
  • The company will retain a 10% minority equity interest worth approximately $200 million, allowing continued collaboration and participation in future upside.
  • IFF expects to receive net cash proceeds of approximately $3.8 billion at closing, which will be prioritized for debt reduction, share repurchases, and reinvestment in high-return growth opportunities.
  • The transaction strengthens IFF's focus on its innovation-driven core businesses: Taste, Scent, and Health & Biosciences, positioning the company for mid-single-digit revenue growth and high-single-digit adjusted EBITDA growth.
  • IFF is reiterating its full-year 2026 guidance with expected sales between $10.5 billion to $10.8 billion and adjusted operating EBITDA between $2.05 billion to $2.15 billion.
  • The divestiture of non-core businesses, including this transaction, has generated nearly $10 billion in gross proceeds over the last several years to support balance sheet improvement.
  • IFF expects comparable currency neutral sales growth of 1% to 4% and adjusted operating EBITDA growth of 3% to 8% in a normalized environment.
  • The Food Ingredients business is described as a globally recognized leader with strong market positions, customer relationships, and a talented team, generating nearly $3.1 billion in annual sales and approximately $430 million of EBITDA.
  • IFF will hold a board seat in the new company following the transaction, ensuring continued strategic oversight and partnership.
Risk Factors
  • The transaction is expected to be dilutive to adjusted earnings per share (EPS) in the first 12 months following closing due to transaction costs and stranded overhead.
  • IFF expects to receive net cash proceeds of approximately $3.8 billion after accounting for rolled-over equity, purchase price adjustments, transaction costs, and taxes, which implies a reduction in total enterprise value compared to the gross $4.3 billion valuation.
  • The divestiture involves selling the Food Ingredients business, which is expected to generate nearly $3.1 billion in annual sales and approximately $430 million in EBITDA in 2025, representing a significant reduction in current revenue scale.
  • IFF will retain a 10% minority equity stake worth roughly $200 million, which means the company does not capture the full value of the divestiture and remains exposed to the performance of the sold business.
Full Analysis
IFF has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners for approximately $4.3 billion in enterprise value, which represents a 10x EBITDA multiple. As part of the deal, IFF will retain a 10% minority equity stake worth roughly $200 million and secure a board seat in the newly formed company to maintain collaboration between the two entities. The Food Ingredients division, which is expected to generate nearly $3.1 billion in annual sales and approximately $430 million in EBITDA in 2025, will be divested to allow IFF to concentrate its resources on its core innovation-driven segments: Taste, Scent, and Health & Biosciences. Upon closing the transaction, which is expected by the end of the second quarter of 2027 subject to regulatory approvals, IFF anticipates receiving net cash proceeds of approximately $3.8 billion after accounting for rolled-over equity, purchase price adjustments, transaction costs, and taxes. The company plans to prioritize using these proceeds for debt reduction to strengthen its balance sheet, targeted share repurchases, and reinvestment in high-return growth opportunities within its remaining portfolio. While the deal is expected to be dilutive to adjusted earnings per share in the first 12 months following closing due to transaction costs and stranded overhead, management believes the long-term strategic benefits of a more focused portfolio and improved cash generation outweigh these near-term impacts. IFF has reiterated its full-year 2026 guidance, projecting sales between $10.5 billion and $10.8 billion and adjusted operating EBITDA between $2.05 billion and $2.15 billion. The company expects comparable currency-neutral sales growth of 1% to 4% and comparable currency-neutral adjusted operating EBITDA growth of 3% to 8%. This divestiture marks the latest step in IFF's ongoing portfolio optimization initiative, which has included the sale of 13 non-core businesses over recent years to generate nearly $10 billion in gross proceeds. The streamlined business will focus on leveraging shared naturals and biosciences capabilities across its three core segments to drive innovation, improve execution, and deliver a stronger long-term financial profile.